AzurRx BioPharma Inc News - AZRX | ADVFN

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Home
Investing
Stocks
USA
NASDAQ
AzurRx BioPharma Inc (AZRX)
AzurRx BioPharma Inc (AZRX) News

AzurRx BioPharma Inc (AZRX)

3.45

0.00

(0.00%)

Closed July 12 4:00PM

Delayed by 15 minutes

3.45

0.00

( 0.00% )

Pre Market: 8:00PM

Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

AzurRx BioPharma Announces Positive Interim Data in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatmen...

Data from first 18 patients indicate MS1819 and PERT combination led to clinically meaningful improvements in...

AzurRx BioPharma Receives Approximately $550K for its 2020 CIR (French Research Tax Credit)

DELRAY BEACH, Fla., May 12, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the...

AzurRx BioPharma to Present at Investor Summit Group’s Q2 Virtual Investor Summit (May 17)

DELRAY BEACH, Fla., May 11, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the...

AzurRx BioPharma CEO Issues Letter to Shareholders

DELRAY BEACH, Fla., April 15, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or...

Notice of Effectiveness (effect)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EFFECTIVENESSEffective Date:April 08,

Post-effective Amendment to Registration Statement (pos Am)

As filed with the Securities and Exchange Commission on April 6, 2021 Registration...

AzurRx BioPharma Initiates Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

“RESERVOIR” trial to evaluate niclosamide’s ability to target SARS-CoV-2 in the GI tract Topline data expected...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC...

Annual Report (10-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC...

AzurRx BioPharma Provides Key Takeaways from Phase 2b OPTION 2 Clinical Trial Topline Results Conference Call

DELRAY BEACH, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or...

AzurRx BioPharma to Report Topline Data from Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

DELRAY BEACH, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or...

AzurRx BioPharma Announces Completion of Enrollment in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treat...

DELRAY BEACH, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or...

AzurRx BioPharma Announces Completion of Enrollment in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

Top-line data expected by end of Q1 2021 DELRAY BEACH, Fla., March 16, 2021 (GLOBE NEWSWIRE) -- AzurRx...

AzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference (March 17-18)

DELRAY BEACH, Fla., March 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”...

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

PROSPECTUS SUPPLEMENT (To the Prospectus Dated June 25, 2019) ...

AzurRx BioPharma

Delayed Upgrade Clock